ArticleDrug design, development and therapy2026
The Natural Compound Cornuside Protects Against Acute Liver Failure Induced by Lipopolysaccharide and D-Galactosamine.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Acute liver failure (ALF) is a life-threatening syndrome characterized by rapid hepatocyte injury, excessive inflammation, and oxidative stress. Cornuside, an iridoid glycoside derived from Methods: ALF was induced in mice by intraperitoneal injection of LPS and D-GalN. Cornuside was administered via tail vein injection either 3 h before or 1 h after LPS/D-GalN administration to assess its preventive and post-injury therapeutic effects, respectively. Serum and liver tissues were harvested 12 h after LPS/D-GalN challenge for the assessment of liver injury, hepatocyte apoptosis, intrahepatic immune cell activation, inflammatory cytokine production, oxidative stress, and ferroptosis-associated markers. Results: Cornuside administration after LPS/D-GalN challenge did not produce significant therapeutic protection against established ALF. In contrast, cornuside pretreatment markedly reduced serum alanine aminotransferase and aspartate aminotransferase levels, alleviated hepatic histopathological injury, and decreased hepatocyte apoptosis. Cornuside pretreatment also suppressed intrahepatic immune cell activation and reduced pro-inflammatory cytokine production. Moreover, cornuside attenuated oxidative stress, as indicated by reduced lipid peroxidation and enhanced antioxidant activity. Mechanistically, cornuside pretreatment modulated ferroptosis-associated signaling, including downregulation of ACSL4 and upregulation of xCT and Gpx4, suggesting that inhibition of ferroptosis may contribute to its hepatoprotective effects. Conclusion: Cornuside provided significant preventive protection against LPS/D-GalN-induced ALF. This protection may be associated with inhibition of inflammation, oxidative stress, and ferroptosis-related ACSL4/xCT/Gpx4 signaling, suggesting cornuside as a potential preventive candidate for ALF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.